📖

hypotheses

wiki page Created: 2026-04-02T17:01:41 By: crosslink-v2 Quality: 50% ✓ SciDEX ID: wiki-hypotheses

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (466)

mentions🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%

related🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%

mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides70%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer65%

mentions🧪APOE Isoform Conversion Therapy65%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones65%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction65%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy65%

mentions🧪Competitive APOE4 Domain Stabilization Peptides65%

mentions🧪APOE Isoform Expression Across Glial Subtypes65%

mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination65%

mentions🧪APOE-TREM2 Interaction Modulation65%

mentions🧪TREM2-mediated microglial tau clearance enhancement65%

mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia65%

related🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides63%

mentions🔬What gene expression changes in the aging mouse brain predic60%

mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen60%

mentions🔬Gene expression changes in aging mouse brain predicting neur60%

mentions🔬Immune atlas neuroinflammation analysis in neurodegeneration60%

mentions🔬Which neural cell types exhibit the most pronounced gene exp60%

mentions🧫s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice 60%

mentions🧫Proposed experiment from debate on Astrocytes adopt A1 (neur60%

mentions🧫s:** - Biochemical binding assays measuring PROTAC selectivi60%

mentions🧫Proposed experiment from debate on Epigenetic clocks and bio60%

mentions🧫Proposed experiment from debate on Microglia activate astroc60%

mentions🧫s:** - Test whether HCN1 knockout specifically in EC layer I60%

mentions🧫s:** - GPR32 knockout in microglia should worsen neuroinflam60%

mentions🧫Proposed experiment from debate on Astrocytes adopt A1 (neur60%

mentions🧫Proposed experiment from debate on Synaptic pruning by micro60%

mentions🧫s:** - ALOX15 overexpression in healthy astrocytes should be60%

mentions🧫Proposed experiment from debate on Epigenetic clocks and bio60%

mentions🧫s:** - Temporal analysis showing mitochondrial defects prece60%

mentions🧫s:** - Test MCU overexpression specifically in layer II neur60%

mentions🧫Proposed experiment from debate on TDP-43 undergoes liquid-l60%

mentions🧫Proposed experiment from debate on Synaptic pruning by micro60%

mentions🧫Proposed experiment from debate on TDP-43 undergoes liquid-l60%

mentions🧫s:** - Compare uptake with/without magnetic particles using 60%

mentions🧫Proposed experiment from debate on Perivascular spaces and g60%

mentions🧫s:** - Test tau spreading in AQP4 knockout vs wild-type mice60%

mentions🧫Proposed experiment from debate on Mitochondrial transfer be60%

mentions🧫s:** - Compare tau strain spreading in EXT1/EXT2 conditional60%

mentions🧫Proposed experiment from debate on Perivascular spaces and g60%

mentions🧫s:** - Single-cell RNA-seq to measure editing efficiency acr60%

mentions🧫Proposed experiment from debate on Mitochondrial transfer be60%

mentions🧫s:** - Dose-response studies showing therapeutic window with60%

mentions🧫Proposed experiment from debate on Senolytics targeting p16/60%

mentions🧫Proposed experiment from debate on Microglia activate astroc60%

mentions🧫Brain Connectivity-Targeted tACS Trial in Early AD60%

mentions🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%

mentions🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal60%

mentions🧫4R-Tau Targeting Therapies for PSP and CBS60%

mentions🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera60%

mentions🧫AAV-LRRK2 IND-Enabling Study Design60%

mentions🧫AAV Serotype Comparison for LRRK2 Knockdown in PD60%

mentions🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi60%

mentions🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau60%

mentions🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back60%

mentions🧫Computational Modeling of Alpha-Synuclein Propagation in PD60%

mentions🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation60%

mentions🧫Alpha-Synuclein Seed Amplification Assay Validation60%

mentions🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation60%

mentions🧫Metabolic Pathway-Targeted Therapy in ALS60%

mentions🧫ALS Progression Rate Heterogeneity — mechanism and biomarker60%

mentions🧫ALS Regional Onset and Spread: Network-Level Staging Model60%

mentions🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk60%

mentions🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti60%

mentions🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?60%

mentions🧫Animal Model Comparison for Neurodegenerative Disease Therap60%

mentions🧫Anti-Tau Immunotherapy Dosing Optimization60%

mentions🧫Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy60%

mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri60%

mentions🧫Antiviral Therapy Trial for Parkinson's Disease60%

mentions🧫ApoE4 Function in Alzheimer's Disease60%

mentions🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&60%

mentions🧫Experiment: Autoimmune Hypothesis Testing in AD60%

mentions🧫Autophagy Enhancement Drug Screening for Neurodegeneration60%

mentions🧫Axonal Transport Dysfunction Validation in Parkinson's 60%

mentions🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#60%

mentions🧫Blood-Based Biomarker Panel for Early AD Detection60%

mentions🧫Blood Biomarker vs Tau PET for Treatment Monitoring60%

mentions🧫Blood-Brain Barrier Aging and Neurodegeneration — From Leaka60%

mentions🧫Brain Connectivity-Targeted tACS Trial in Early AD60%

mentions🧫Brainstem Circuit Modulation for PSP60%

mentions🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT60%

mentions🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study60%

mentions🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 60%

mentions🧫CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi60%

mentions🧫cGAS-STING Pathway Validation Study in Parkinson's Dise60%

mentions🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 60%

mentions🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M60%

mentions🧫Combination Therapy Sequencing in Parkinson's Disease60%

mentions🧫CRISPR Gene Correction Approaches for CBS/PSP60%

mentions🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa60%

mentions🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera60%

mentions🧫DLB Cognitive Fluctuation Mechanism Experiment60%

mentions🧫Genetic Risk Modifiers in DLB Phenotype60%

mentions🧫Tau Co-Pathology in DLB Clinical Heterogeneity60%

mentions🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras60%

mentions🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#60%

mentions🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i60%

mentions🧫Selective Vulnerability of Dopaminergic Neurons — Mechanism 60%

mentions🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera60%

mentions🧫Endocannabinoid System Dysfunction Validation in Parkinson&#60%

mentions🧫Environmental Exposure Causal Attribution in ALS — Experimen60%

mentions🧫Epigenetic Clocks in Neurodegeneration — Causal Drivers or P60%

mentions🧫Epigenetic Dysregulation in Huntington's Disease — Ther60%

mentions🧫Epigenetic Dysregulation Validation in Parkinson's Dise60%

mentions🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa60%

mentions🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De60%

mentions🧫Exercise-BDNF-Mitophagy Biomarker Study in PD60%

mentions🧫Experiment Index60%

mentions🧫Ferroptosis Validation in Parkinson's Disease60%

mentions🧫Frontal and Temporal Lobe Selective Vulnerability in FTD — M60%

mentions🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud60%

mentions🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation60%

mentions🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio60%

mentions🧫Gap Junction Dysfunction Validation in Parkinson's Dise60%

mentions🧫GLP-1 Agonist Neuroprotection Mechanism in PD60%

mentions🧫GLP-1 Agonist Responder Prediction Study — Precision Medicin60%

mentions🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&60%

mentions🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me60%

mentions🧫Iron Dyshomeostasis in MSA Pathogenesis Experiment60%

mentions🧫Levodopa-Induced Dyskinesias Mechanism — Experiment Design60%

mentions🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre60%

mentions🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas60%

mentions🧫Cytochrome Therapeutics60%

mentions🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson60%

mentions🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown60%

mentions🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design60%

mentions🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne60%

mentions🧫Macroautophagy Dysfunction in PD - Experiment Design60%

mentions🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P60%

mentions🧫Validation: Membrane-Nucleation in iPSC Neurons60%

mentions🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr60%

mentions🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise60%

mentions🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 60%

mentions🧫Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic 60%

mentions🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag60%

mentions🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech60%

mentions🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr60%

mentions🧫Microglial Contributions to Huntington's Disease Pathog60%

mentions🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis60%

mentions🧫Mixed Pathology Effects on Parkinson's Disease Progress60%

mentions🧫MLCS Quantification in Parkinson's Disease60%

mentions🧫Experiment: Multi-Ethnic PD GWAS60%

mentions🧫Multiscale Computational Modeling of Protein Aggregation Kin60%

mentions🧫N-of-1 Clinical Trial Design for CBS/PSP60%

mentions🧫Neural Oscillation Dysfunction Validation in Parkinson'60%

mentions🧫Neural Stem Cell Therapy for Alzheimer's Disease60%

mentions🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise60%

mentions🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper60%

mentions🧫Non-Motor Symptom Progression in Parkinson's Disease — 60%

mentions🧫Normal Aging to Alzheimer's Disease Transition Trigger 60%

mentions🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%

mentions🧫NPH Glymphatic System Interaction Experiment60%

mentions🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#60%

mentions🧫Parkinson's Disease Subtype Classification — Precision 60%

mentions🧫Peroxisomal Dysfunction Validation in Parkinson's Disea60%

mentions🧫Peroxisome Dysfunction Validation in Parkinson's Diseas60%

mentions🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers60%

mentions🧫Presymptomatic GRN Carrier Intervention Timing — Biomarker-G60%

mentions🧫Pre-Symptomatic Detection and Intervention Timing in Genetic60%

mentions🧫Prion Strain Diversity and Selective Vulnerability in CJD60%

mentions🧫Prion Strain Diversity and Selective Vulnerability60%

mentions🧫Prodromal Parkinson's Disease Biomarker Development — E60%

mentions🧫Progranulin Replacement Therapy for FTD — Vector Development60%

mentions🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD60%

mentions🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin60%

mentions🧫Protein Aggregation Kinetic Validation Results60%

mentions🧫PSP and CBS Biomarker Validation Study60%

mentions🧫Purinergic Signaling Dysfunction Validation in Parkinson60%

mentions🧫Regulated Necrosis Validation Study in Parkinson's Dise60%

mentions🧫Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel60%

mentions🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease60%

mentions🧫Experiment Scoring Methodology60%

mentions🧫Selective Neuronal Vulnerability to Aging — Mapping Why Spec60%

mentions🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#60%

mentions🧫Sex Differences in Alzheimer's Disease — mechanisms and60%

mentions🧫Sirtuin Dysfunction Validation in Parkinson's Disease60%

mentions🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D60%

mentions🧫Sleep and Circadian Dysfunction as Driver of Neurodegenerati60%

mentions🧫Sleep Disruption and Alzheimer's Disease — mechanism an60%

mentions🧫Sleep and Respiratory Network Interaction in ALS — Experimen60%

mentions🧫Stress Granule Dysfunction Validation in Parkinson's Di60%

mentions🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&60%

mentions🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki60%

mentions🧫Tau Pathology Initiation Zone Identification60%

mentions🧫Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo60%

mentions🧫Tau Propagation Causality Test — Does Tau Spread Drive Neuro60%

mentions🧫Tau Spreading Network Mapping via Spatial Transcriptomics in60%

mentions🧫Traumatic Brain Injury and Alzheimer's Disease Relation60%

mentions🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal60%

mentions🧫TDP-43 PET Ligand Development for FTD and ALS60%

mentions🧫Experiment Validation: In vitro ThT Assay60%

mentions🧫TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism an60%

mentions🧫Tau ASO Therapy60%

mentions🧫Microglial TREM2 Agonist In Vivo Efficacy60%

mentions🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim60%

mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia60%

mentions🧫Vascular Contribution to Alzheimer's Disease — Beyond A60%

mentions🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol60%

mentions🧫Viral Infections and Alzheimer's Disease — causal mecha60%

mentions🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des60%

mentions🧫Wilson Disease Neurodegeneration: Mechanism and Therapeutic 60%

related🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer58%

related🧪APOE Isoform Conversion Therapy58%

related🧪APOE4 Allosteric Rescue via Small Molecule Chaperones58%

related🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction58%

related🧪Targeted APOE4-to-APOE3 Base Editing Therapy58%

related🧪Competitive APOE4 Domain Stabilization Peptides58%

related🧪APOE Isoform Expression Across Glial Subtypes58%

related🧪TREM2 Conformational Stabilizers for Synaptic Discrimination58%

related🧪APOE-TREM2 Interaction Modulation58%

related🧪TREM2-mediated microglial tau clearance enhancement58%

related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia58%

related🔬What gene expression changes in the aging mouse brain predic54%

related🔬Comprehensive analysis of immune cell subtypes in neurodegen54%

related🔬Gene expression changes in aging mouse brain predicting neur54%

related🔬Immune atlas neuroinflammation analysis in neurodegeneration54%

related🔬Which neural cell types exhibit the most pronounced gene exp54%

related🧫s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice 54%

related🧫Proposed experiment from debate on Astrocytes adopt A1 (neur54%

related🧫s:** - Biochemical binding assays measuring PROTAC selectivi54%

related🧫Proposed experiment from debate on Epigenetic clocks and bio54%

related🧫Proposed experiment from debate on Microglia activate astroc54%

related🧫s:** - Test whether HCN1 knockout specifically in EC layer I54%

related🧫s:** - GPR32 knockout in microglia should worsen neuroinflam54%

related🧫Proposed experiment from debate on Astrocytes adopt A1 (neur54%

related🧫Proposed experiment from debate on Synaptic pruning by micro54%

related🧫s:** - ALOX15 overexpression in healthy astrocytes should be54%

related🧫Proposed experiment from debate on Epigenetic clocks and bio54%

related🧫s:** - Temporal analysis showing mitochondrial defects prece54%

related🧫s:** - Test MCU overexpression specifically in layer II neur54%

related🧫Proposed experiment from debate on TDP-43 undergoes liquid-l54%

related🧫Proposed experiment from debate on Synaptic pruning by micro54%

related🧫Proposed experiment from debate on TDP-43 undergoes liquid-l54%

related🧫s:** - Compare uptake with/without magnetic particles using 54%

related🧫Proposed experiment from debate on Perivascular spaces and g54%

related🧫s:** - Test tau spreading in AQP4 knockout vs wild-type mice54%

related🧫Proposed experiment from debate on Mitochondrial transfer be54%

related🧫s:** - Compare tau strain spreading in EXT1/EXT2 conditional54%

related🧫Proposed experiment from debate on Perivascular spaces and g54%

related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr54%

related🧫Proposed experiment from debate on Mitochondrial transfer be54%

related🧫s:** - Dose-response studies showing therapeutic window with54%

related🧫Proposed experiment from debate on Senolytics targeting p16/54%

related🧫Proposed experiment from debate on Microglia activate astroc54%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%

related🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal54%

related🧫4R-Tau Targeting Therapies for PSP and CBS54%

related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera54%

related🧫AAV-LRRK2 IND-Enabling Study Design54%

related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD54%

related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi54%

related🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau54%

related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back54%

related🧫Computational Modeling of Alpha-Synuclein Propagation in PD54%

related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation54%

related🧫Alpha-Synuclein Seed Amplification Assay Validation54%

related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation54%

related🧫Metabolic Pathway-Targeted Therapy in ALS54%

related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker54%

related🧫ALS Regional Onset and Spread: Network-Level Staging Model54%

related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk54%

related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti54%

related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?54%

related🧫Animal Model Comparison for Neurodegenerative Disease Therap54%

related🧫Anti-Tau Immunotherapy Dosing Optimization54%

related🧫Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy54%

related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri54%

related🧫Antiviral Therapy Trial for Parkinson's Disease54%

related🧫ApoE4 Function in Alzheimer's Disease54%

related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&54%

related🧫Experiment: Autoimmune Hypothesis Testing in AD54%

related🧫Autophagy Enhancement Drug Screening for Neurodegeneration54%

related🧫Axonal Transport Dysfunction Validation in Parkinson's 54%

related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#54%

related🧫Blood-Based Biomarker Panel for Early AD Detection54%

related🧫Blood Biomarker vs Tau PET for Treatment Monitoring54%

related🧫Blood-Brain Barrier Aging and Neurodegeneration — From Leaka54%

related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%

related🧫Brainstem Circuit Modulation for PSP54%

related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT54%

related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study54%

related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 54%

related🧫CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi54%

related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise54%

related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 54%

related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M54%

related🧫Combination Therapy Sequencing in Parkinson's Disease54%

related🧫CRISPR Gene Correction Approaches for CBS/PSP54%

related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa54%

related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera54%

related🧫DLB Cognitive Fluctuation Mechanism Experiment54%

related🧫Genetic Risk Modifiers in DLB Phenotype54%

related🧫Tau Co-Pathology in DLB Clinical Heterogeneity54%

related🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras54%

related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#54%

related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i54%

related🧫Selective Vulnerability of Dopaminergic Neurons — Mechanism 54%

related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera54%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#54%

related🧫Environmental Exposure Causal Attribution in ALS — Experimen54%

related🧫Epigenetic Clocks in Neurodegeneration — Causal Drivers or P54%

related🧫Epigenetic Dysregulation in Huntington's Disease — Ther54%

related🧫Epigenetic Dysregulation Validation in Parkinson's Dise54%

related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa54%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De54%

related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD54%

related🧫Experiment Index54%

related🧫Ferroptosis Validation in Parkinson's Disease54%

related🧫Frontal and Temporal Lobe Selective Vulnerability in FTD — M54%

related🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud54%

related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation54%

related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio54%

related🧫Gap Junction Dysfunction Validation in Parkinson's Dise54%

related🧫GLP-1 Agonist Neuroprotection Mechanism in PD54%

related🧫GLP-1 Agonist Responder Prediction Study — Precision Medicin54%

related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&54%

related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me54%

related🧫Iron Dyshomeostasis in MSA Pathogenesis Experiment54%

related🧫Levodopa-Induced Dyskinesias Mechanism — Experiment Design54%

related🧫Levodopa Response Determinants in PSP — Biomarker-Guided Pre54%

related🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas54%

related🧫Cytochrome Therapeutics54%

related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson54%

related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown54%

related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design54%

related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne54%

related🧫Macroautophagy Dysfunction in PD - Experiment Design54%

related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P54%

related🧫Validation: Membrane-Nucleation in iPSC Neurons54%

related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr54%

related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise54%

related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 54%

related🧫Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic 54%

related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag54%

related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech54%

related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr54%

related🧫Microglial Contributions to Huntington's Disease Pathog54%

related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis54%

related🧫Mixed Pathology Effects on Parkinson's Disease Progress54%

related🧫MLCS Quantification in Parkinson's Disease54%

related🧫Experiment: Multi-Ethnic PD GWAS54%

related🧫Multiscale Computational Modeling of Protein Aggregation Kin54%

related🧫N-of-1 Clinical Trial Design for CBS/PSP54%

related🧫Neural Oscillation Dysfunction Validation in Parkinson'54%

related🧫Neural Stem Cell Therapy for Alzheimer's Disease54%

related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise54%

related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper54%

related🧫Non-Motor Symptom Progression in Parkinson's Disease — 54%

related🧫Normal Aging to Alzheimer's Disease Transition Trigger 54%

related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%

related🧫NPH Glymphatic System Interaction Experiment54%

related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#54%

related🧫Parkinson's Disease Subtype Classification — Precision 54%

related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea54%

related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas54%

related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers54%

related🧫Presymptomatic GRN Carrier Intervention Timing — Biomarker-G54%

related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic54%

related🧫Prion Strain Diversity and Selective Vulnerability in CJD54%

related🧫Prion Strain Diversity and Selective Vulnerability54%

related🧫Prodromal Parkinson's Disease Biomarker Development — E54%

related🧫Progranulin Replacement Therapy for FTD — Vector Development54%

related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD54%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin54%

related🧫Protein Aggregation Kinetic Validation Results54%

related🧫PSP and CBS Biomarker Validation Study54%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson54%

related🧫Regulated Necrosis Validation Study in Parkinson's Dise54%

related🧫Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel54%

related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease54%

related🧫Experiment Scoring Methodology54%

related🧫Selective Neuronal Vulnerability to Aging — Mapping Why Spec54%

related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#54%

related🧫Sex Differences in Alzheimer's Disease — mechanisms and54%

related🧫Sirtuin Dysfunction Validation in Parkinson's Disease54%

related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D54%

related🧫Sleep and Circadian Dysfunction as Driver of Neurodegenerati54%

related🧫Sleep Disruption and Alzheimer's Disease — mechanism an54%

related🧫Sleep and Respiratory Network Interaction in ALS — Experimen54%

related🧫Stress Granule Dysfunction Validation in Parkinson's Di54%

related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&54%

related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki54%

related🧫Tau Pathology Initiation Zone Identification54%

related🧫Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo54%

related🧫Tau Propagation Causality Test — Does Tau Spread Drive Neuro54%

related🧫Tau Spreading Network Mapping via Spatial Transcriptomics in54%

related🧫Traumatic Brain Injury and Alzheimer's Disease Relation54%

related🧫Biomechanical Impact Profiles and Chronic Traumatic Encephal54%

related🧫TDP-43 PET Ligand Development for FTD and ALS54%

related🧫Experiment Validation: In vitro ThT Assay54%

related🧫TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism an54%

related🧫Tau ASO Therapy54%

related🧫Microglial TREM2 Agonist In Vivo Efficacy54%

related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim54%

related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia54%

related🧫Vascular Contribution to Alzheimer's Disease — Beyond A54%

related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol54%

related🧫Viral Infections and Alzheimer's Disease — causal mecha54%

related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des54%

related🧫Wilson Disease Neurodegeneration: Mechanism and Therapeutic 54%

mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna50%

mentions🧪Vocal Cord Neuroplasticity Stimulation50%

mentions🧪Vagal Afferent Microbial Signal Modulation50%

mentions🧪Brain Insulin Resistance with Glucose Transporter Dysfunctio50%

mentions🧪Astrocytic Connexin-43 Upregulation Enhances Neuroprotective50%

mentions🧪Restoring Neuroprotective Tryptophan Metabolism via Targeted50%

mentions🧪Liquid-Liquid Phase Separation Modifier Therapy50%

mentions🧪Epigenetic Memory Reprogramming for Alzheimer's Disease50%

mentions🧪PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor50%

mentions🧪TREM2-Mediated Selective Aggregate Clearance Pathway50%

mentions🧪Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Tar50%

mentions🧪Targeted Butyrate Supplementation for Microglial Phenotype M50%

mentions🧪Synthetic Biology Approach: Designer Mitochondrial Export Sy50%

mentions🧪The Glial Ketone Metabolic Shunt Hypothesis50%

mentions🧪APOE-Dependent Autophagy Restoration50%

mentions🧪APOE-Mediated Synaptic Lipid Raft Stabilization50%

mentions🧪Proteostasis Enhancement via APOE Chaperone Targeting50%

mentions🧪TREM2-Dependent Microglial Senescence Transition50%

mentions🧪Context-Dependent CRISPR Activation in Specific Neuronal Sub50%

mentions🧪RNA-Binding Competition Therapy for TDP-43 Cross-Seeding50%

mentions🧪Optogenetic Control of Mitochondrial Transfer Networks50%

mentions🧪Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci50%

mentions🧪Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cro50%

mentions🧪Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro50%

mentions🧪Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy50%

mentions🧪Gap Junction Hemichannel Modulation for Controlled Mitochond50%

mentions🧪Programmable Neuronal Circuit Repair via Epigenetic CRISPR50%

mentions🧪Complement-Mediated Synaptic Pruning Dysregulation50%

mentions🧪HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor50%

mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy50%

mentions🧪Correcting Gut Microbial Dopamine Imbalance to Support Syste50%

mentions🧪Transglutaminase-2 Cross-Linking Inhibition Strategy50%

mentions🧪Microglia-Derived Extracellular Vesicle Engineering for Targ50%

mentions🧪The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction50%

mentions🧪TFEB-PGC1α Mitochondrial-Lysosomal Decoupling50%

mentions🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro50%

related🔬What are the mechanisms underlying digital biomarkers and ai50%

related🔬What are the mechanisms underlying what are the mechanisms b50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

related🔬What are the mechanisms underlying digital biomarkers and ai50%

related🔬What are the mechanisms underlying what are the mechanisms b50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

related🔬CRISPR-based therapeutic approaches for neurodegenerative di50%

mentions🧫Multi-omics analysis of myricanol effects on gene expression44%

mentions🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio44%

mentions🧫tACS Connectivity Trial in Early Alzheimer's44%

mentions🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design44%

related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna40%

related🧪Vocal Cord Neuroplasticity Stimulation40%

related🧪Vagal Afferent Microbial Signal Modulation40%